Real-world use of multigene signatures in early breast cancer: differences to clinical trials.
Luca LicataRita De SanctisAndrea VingianiDeborah CosentiniMonica IorfidaElena Rota CaremoliIsabella SassiBethania FernandesAndrea GianattiElena Guerini-RoccoClaudia ZambelliElisabetta MunzoneEdda Lucia SimonciniCarlo TondiniOreste Davide GentiliniAlberto ZambelliGiancarlo PruneriGiampaolo BianchiniPublished in: Breast cancer research and treatment (2024)
In this real-world series, Oncotype DX was the test almost exclusively used. Despite reimbursement being linked to pre-test chemotherapy recommendation, almost 3/4 patients resulted in the low-RS group. The significant proportion of node-positive patients ≤ 50 years tested indicates that oncologists considered Oncotype DX informative also in this population.
Keyphrases
- end stage renal disease
- clinical trial
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- early breast cancer
- randomized controlled trial
- lymph node
- genome wide
- palliative care
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- open label
- advanced cancer